An interventional study of Ultrasound and Sham (No Treatment) in Neuropathic Pain and Chronic Pain, sponsored by Stanford University. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-07.
Sponsored by Stanford University · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Neuralgia by Stanford University — 6 open to participants now, 6 under way, 2 of them phase 3. Neuralgia · Stanford University.
Among the 12 studies in Neuralgia by Stanford University, this one is the 7th largest by planned enrollment, is one of 2 that started in 2026, is one of 5 with no phase, and was the 11th registered.
1,103 studies on the registry are indexed under Neuralgia; 243 are open to participants now.
Browse Neuralgia studies →6 of the 12 studies in Neuralgia by Stanford University are open now, in 1 country. Recruiting first, the newest first:
Stanford University · Sites in United States
Ages 18+
Stanford University · Sites in United States
Ages 18+
Stanford University · Sites in United States
Ages 18+
Stanford University · Sites in United States
Ages 18+ · Healthy volunteers
Stanford University
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 155 Neuralgia studies recruiting now, 79 (51%) set no upper age limit and 44 (28%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 2 · Phase 3 2
First in 2014; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is above the median of 52 across 833 interventional studies indexed under Neuralgia.
Median enrollment 93 across the 12 interventional studies. Of the 4 that completed or were terminated, 1 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
Stanford University is the lead sponsor of 2,171 studies on the registry; 425 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.
1 of the studies in Neuralgia by Stanford University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07572591Stanford UniversityUltrasound for Peripheral Nerve Modulation | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Neuralgia by Stanford University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates an ultrasound device designed to reduce pain by targeting peripheral nerves without surgery or medication. The device is placed on the skin over the area of pain and delivers controlled ultrasound stimulation.
Adults with nerve-related pain will participate in a single study visit that includes stimulation sessions and pain assessments.
The goal of this study is to determine whether non-invasive ultrasound can safely and effectively reduce pain and to assess whether this approach is practical for future clinical use.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants undergo sham ultrasound stimulation that replicates all procedural aspects of active treatment without delivery of therapeutic acoustic energy.
Device: Sham (No Treatment)
Participants receive ultrasound stimulation at predefined parameters to evaluate neuromodulatory effects on the target peripheral nerve.
Device: Ultrasound
Non-invasive focused ultrasound stimulation is applied to a target peripheral nerve.
Sham stimulation replicates all procedural aspects of active ultrasound neuromodulation, including device placement and operation, without delivery of therapeutic acoustic energy. This condition serves as a control to account for placebo and procedural effects.
Incidence of Device-Related Adverse Events
Assessment of the number and severity of device- and procedure-related adverse events associated with focused ultrasound neuromodulation. Events will be graded according to standard clinical criteria, including pain, skin irritation, thermal effects, or neurologic symptoms.
Time frame: From treatment to the next day (up to two days)
Change in Numerical Pain Rating Scale
Participant-reported tolerability assessed using a numerical pain rating scale (e.g., discomfort or pain score during stimulation). The scale ranges from 1 (no pain) through 10 (worst pain).
Time frame: During, immediately after each stimulation block, and one day after the treatment (up to two days)
Plan to share: No — Individual participant data (IPD) will not be shared at this stage due to the early feasibility nature of the study and the small sample size, which may increase the risk of participant re-identification. De-identified, aggregated results will be reported in publications and presentations.
Start is estimated for Jun 2026; primary completion for Jun 2027, 12 months later.
Of 249 non-industry interventional studies with no phase under Neuralgia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 41. This study's planned 12 months is below that.
Counting every sponsor, half of 267 studies reached it within 24 months; a quarter within 10 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.